Valeant sells iNova Pharmaceuticals for $930M — 4 insights

Valeant Pharmaceuticals entered into an agreement to sell iNova Pharmaceuticals to a company owned by Pacific Equity Partners and The Carlyle Group for $930 million.

Here's what you should know:

1. Valeant CEO Joseph Papa said in a release Valeant made the sale to "strengthen our balance sheet."

2. iNova sold prescription and over-the-counter products for weight management, pain management, cardiology as well as cough and cold medicine.

3. Valeant will continue to sell in markets where iNova is present through its Bausch + Lomb franchise.

4. Valeant will use the $930 million to pay off term loan debt under its senior secured credit facility.

More articles on improving health:
Wisconsin health system expand services through new clinic, provider — 3 insights
XBiotech discontinues phase III study for colorectal cancer antibody therapy — 4 insights
Gastroenterologists ignoring H.pylori guidelines, survey says — 3 insights

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast